SBR 2021 Congresso Brasileiro De Reumatologia 2021
DOI: 10.47660/cbr.2021.2236
|View full text |Cite
|
Sign up to set email alerts
|

Sars-Cov-2 Vaccine in Spondyloarthritis Patients: Overall Moderate/High Immunogenicity Impaired by Immunosuppressants and Biological Therapy

Abstract: BACKGROUNDWe recently reported an attenuate immunogenicity in patients with autoimmune rheumatic diseases. However, the effect of spondyloarthritis (SpA) and its treatment on COVID-19 vaccine immunogenicity remains to be determined for this group of patients. We therefore aimed to evaluate humoral immune responses to inactivated SARS-CoV-2 vaccine (CoronaVac) in patients with SpA (axial spondyloarthritis and psoriatic arthritis) taking DMARDs and commonly used targeted biological therapies, compared with a con… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles